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AbstrAct 
Objective To evaluate response duration and identify 
predictors of transitioning into and out of the response 
state in patients with SLE receiving standard of care (SoC) 
in 52-week clinical trials.
Methods A multistate model (MSM) allowing for 
bidirectional transitions between response and non-
response states was fit to data on 759 patients with SLE 
with active disease randomised to SoC. The probability 
of being in response at 52 weeks, average duration of 
response (sojourn time) and mean total time in response 
for SLE Responder Index (SRI-4, SRI-5, SRI-6) and 
BILAG-based Composite Lupus Assessment (BICLA) were 
estimated. Predictors of attainment and loss of SRI-5 
response were also assessed.
Results The MSM estimated probability of being in 
response at 52 weeks ranged from 42% (SRI-6) to 61% 
(SRI-4). Mean duration of response ranged from 20.4 
weeks (BICLA) to 31.5 weeks (SRI-4). Mean total time in 
response was 16.4–24.8 weeks. Baseline characteristics 
predictive of shorter SRI-5 response duration were African 
descent (p=0.005), longer history of disease (p=0.03), 
higher anti-dsDNA antibody titres (p=0.039), lower 
lymphocyte count (p=0.008) and lower haemoglobin 
(p=0.006). Younger age (p<0.001) and higher protein/
creatinine ratio (p<0.001) were associated with higher 
likelihood of achieving SRI-5 but also shorter response 
duration.
Conclusion Factors associated with disease severity were 
more predictive of shorter response duration than of 52-
week response status. Analysing landmark response rates 
and response duration using MSM may be a more powerful 
way to distinguish effective investigational treatments from 
background SoC, although this remains to be evaluated in 
future trials.
IntROduCtIOn
The primary endpoint in SLE trials is usually 
response to therapy at a landmark visit, 
for example, 52 weeks. A limitation with 
this outcome is that lupus symptoms and a 
patient’s response status can fluctuate over 
time so that analysing data from a single visit 
to evaluate the effect of a treatment or other 
clinical factor may lead to misleading conclu-
sions. For example, two groups may show 
similar response rates at a particular point 
in time, but the duration of response may be 
longer in one group than the other and this 
difference would not be detected in a simple 
cross-sectional analysis. Assessing the duration 
of response once response is achieved (ie, 
sojourn time) as well as the total time spent 
in the response state during follow-up would 
yield more information about the effects of 
the treatments under investigation than would 
a conventional cross-sectional approach, yet 
these aspects of the disease profile have not 
been investigated in prior SLE trials.
A difficulty with response duration as 
an endpoint is that the optimal analytic 
approach for evaluating it is not clear. If we 
consider a 52-week trial, one might analyse 
response duration only among those who 
were observed to be responders at 52 weeks 
and assess how long the response was contin-
uously maintained up until that time point. 
This method, however, will result in selec-
tion bias since patients who responded at 
earlier visits but subsequently relapsed are 
ignored. Estimating response duration is 
further complicated by missed visits, early 
dropouts and follow-up schedules that result 
in intermittent rather than continuous eval-
uation of patients. Thus, the exact times of 
achieving and losing response are generally 
not observed. Furthermore, the common 
approach of assuming that missing outcomes 
are non-responses (ie, non-responder imputa-
tion) is a strong assumption and can result in 
underestimating the response duration.
In this paper, we apply a multistate 
Markov model (MSM) to analyse response 
duration with complex longitudinal data and 
examine patient characteristics that predict 
transitions into and out of the response state. 
Knowing the latter information for patients 
who receive standard of care (SoC) and 
placebo in trials may not provide new insights 
into patient prognosis, but could be useful for 
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the development of entry criteria that would reduce high 
placebo response rates in future trials.
MSM models are appropriate for investigating a disease 
process in which individuals can move between different 
clinical states. In the SLE clinical trial setting, the two 
main clinical states of interest are response and non-re-
sponse. With MSM models, one can estimate the propor-
tion of individuals who will be in various states at some 
point in the future, and the expected time that a subject 
spends in each state. Most importantly, the method makes 
efficient use of incomplete follow-up data when only brief 
segments of an individual’s disease history are available, 
and it can handle different types of censoring due to 
losses to follow-up, periodic monitoring of patients and 
missed visits.
The MSM approach has been applied to study the 
different clinical stages of HIV/AIDS, cancer and other 
illnesses, and was recently used to identify predictors of 
damage accrual in patients with SLE,1 2 and change in 
lupus nephritis outcomes.3 The objective in this paper 
is to fit an MSM to characterise response duration using 
different measures of SLE response, and explore which 
baseline variables predict transitions into and out of 
the response state during follow-up in a large group of 
patients with moderate to severe SLE who received SoC 
in 52-week randomised clinical trials.
MethOds
Data on 759 patients with SLE with active disease (SLE 
Disease Activity Index (SLEDAI) ≥6 at entry) who were 
randomised to placebo plus SoC in 52-week trials were 
obtained from the Collective Data Analysis Initiative 
(CDAI) database of the Lupus Foundation of America 
(LFA). The LFA established the CDAI so that data from 
the placebo/SoC arms of previous SLE clinical trials can 
be used to improve the design and conduct of future 
studies.4 5 Permissible SoC included non-steroidal anti-in-
flammatory drugs, corticosteroids, antimalarials and 
immunosuppressants (eg, azathioprine, methotrexate, 
mycophenolate mofetil). Increases to the steroid dose 
were allowed only during the first 24 weeks of the trial. 
Patients were assessed for clinical outcomes approxi-
mately every 4 weeks during follow-up. Ethics committee 
approvals were obtained according to local regulations 
and informed consent procedures were completed in 
accordance with the Helsinki Declaration version in 
effect at the time of each trial.
The following SLE response endpoints (without medi-
cation stipulations) were analysed: SLE Responder Index 
(SRI-4, SRI-5, SRI-6) and the British Isles Lupus Assess-
ment Group (BILAG)-based Composite Lupus Assess-
ment (BICLA). For BICLA, the available sample size was 
smaller (n=437) because only patients with at least one 
BILAG A or two or more BILAG B at enrolment were 
included.
A two-state (response, non-response) reversible 
model was fit to estimate the probability of being in 
response at 52 weeks, average duration of response 
(sojourn time) and mean total time in response for the 
different response measures. All patients are assumed 
to be in the non-response state at enrolment and can 
transition back and forth between the response and 
non-response states multiple times during the 52-week 
follow-up period.
To identify predictors of attainment and loss of 
response, we focused on SRI-5 which has been used as 
the primary endpoint in recent SLE trials.6 7 The effects 
of the variables on the two transition intensities (also 
known as transition rates or hazards) for moving into and 
out of SRI-5 response were modelled using the following 
proportional hazards regression approach:
 λij(t|x) = λijo(t)exp(x
Tβij) 
where λij(t|x) is the transition intensity at time t between 
states i and j (i, j=1 or 2 for non-response and response 
states, respectively) given x = (x1,…,xp)
T, a (p x 1) vector 
of covariates which is assumed to be constant over time 
and across states; λijo (t) is the baseline transition inten-
sity, and βij= (βij1,…,βijp)T is the corresponding vector of 
regression coefficients which quantifies the effect of x on 
transitions between states i and j. The effect of a specific 
predictor variable, xk, on the i to j transition intensity can 
be estimated by exp (βijk), which is equal to the ratio of 
the transition intensities corresponding to a unit increase 
in xk, assuming the other covariates are held constant.
The variables in table 1 were considered for inclusion 
in the regression model and parameters were estimated 
using the maximum likelihood approach. Bivariate 
analyses were initially performed, and variables which 
were significant at the p<0.10 level, as well as those 
considered clinically important a priori, were consid-
ered for inclusion in the final model which was deter-
mined using a stepwise variable selection approach. 
Only the covariates with p<0.05 were retained in the 
final model. Since the missing data rates were less than 
10% for the covariates in the final model, a listwise dele-
tion approach based on the available data was used to 
handle the missing values.
We initially assumed a time homogeneous model 
where the baseline transition intensities are assumed 
to be constant over time, that is, λijo (t) = λijo, where 
λ12o denotes the baseline transition rate between 
non-response and response (ie, improvement) and 
λ21o denotes the transition rate between response and 
non-response (ie, worsening). Given that steroid doses 
could be increased in the first 24 weeks, we also fit in 
sensitivity analysis a non-homogeneous MSM model 
where the baseline transition intensities between states 
were assumed to be piecewise constant with change 
points at 12 and 24 weeks. 
All analyses were performed using the R statistical 
software package, msm (V.1.6.4), which was devel-
oped specifically for the analysis of multistate disease 
processes where the exact transition times between 
states are not known.8 9
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Table 1  Baseline demographic and clinical characteristics 
(n=759)
Age (years) 39.8 (12.0)
Female, n (%) 714 (94)
Race, n (%)
  American Indian or Alaska Native 97 (13)
  Asian 115 (15)
  Black or African American 86 (11)
  Multiple 8 (1)
  White 453 (60)
Immunosuppressants, n (%)
  Azathioprine 139 (18)
  Mycophenolate mofetil 60 (8)
  Methotrexate 80 (11)
SLEDAI 10.3 (3.6)
Disease duration (years) 7.0 (7.0)
BILAG 14.6 (7.2)
Organ system has an A or B at baseline, 
n (%)
  Constitutional 16 (2)
  Mucocutaneous 520 (69)
  Musculoskeletal 471 (62)
  Cardiorespiratory 54 (7.1)
  Neuropsychiatric 9 (1)
  Gastrointestinal 12 (2)
  Renal 93 (12)
  Ophthalmic 7 (1)
  Haematological 1 (0.1)
PGA 45.9 (16.3)
White cells (×109/L) 5.9 (2.4)
Lymphocytes (×109/L) 1.3 (0.7)
Neutrophils (×109/L) 4.1 (2.1)
CD19 (%) 12.8 (8.1)
Haemoglobin (g/dL) 12.4 (1.4)
C3 (g/L) 0.99 (0.31)
C4 (g/L) 0.17 (0.10)
Anti-dsDNA (IU/mL) 110.3 (114.7)
Anti-dsDNA ≥30 IU/mL, n (%) 451 (59.6%)
IgG (g/L) 15.2 (5.2)
IgM (g/L) 1.2 (0.8)
IgA (g/L) 3.1 (1.6)
Anti-Sm (U/mL) 20.3 (34.5)
Anti-RNP (U/mL) 42.3 (53.5)
Anti-SSA/Ro (U/mL) 55.3 (62.3)
Anti-SSB/La  (U/mL) 20.2 (36.6)
Protein/creatinine>500 mg/g, n (%) 60 (7.9)
Except where indicated, values are the mean±SD.
BILAG, British Isles Lupus Assessment Group; PGA, 
phosphoglyceric acid; SLEDAI, SLE Disease Activity Index.
Results
Seven hundred and fifty-nine patients were included in 
the analysis (table 1): 94% were female, 60% were White 
and the mean age was 39.8 years (SD 12.0). The mean 
SLEDAI score at baseline was 10.3 (SD 3.6) and patients 
had disease on average for 7 years (SD 7.0). Eighteen 
per cent of patients were on azathioprine, 8% on myco-
phenolate mofetil and 11% on methotrexate as back-
ground medications. Over 60% of patients had a BILAG 
A or B score in the mucocutaneous and musculoskel-
etal organ systems; 12% in the renal organ. Twenty-four 
per cent of the subjects discontinued the trial early.
Figure 1 shows examples of different patterns of longitu-
dinal data that can complicate the estimation of response 
duration. For example, the first subject (ID 1001) 
achieved a response at months 3–5 and then dropped 
out of the trial. The third subject (ID 1003) achieved and 
sustained a response for the first 3 months, missed visit 4, 
was a non-responder at months 5–8 and then responded 
continuously again at months 9–12.
Table 2 is a frequency table of pairs of consecutive visits 
from all subjects cross-classified by response status at the 
initial and subsequent visits for the different response 
outcomes. For SRI-4, there were 4530 pairs of consecu-
tive visits in which non-response was the initial state and 
of these, 795 (17.5%) were a response at the subsequent 
visit. Among the 3648 visit pairs where response was the 
initial state, 395 (10.8%) were a non-response at the next 
visit. For SRI-5, SRI-6 and BICLA, 11.0%, 10.7% and 
16.6% of visit pairs, respectively, which had non-response 
at the first visit were followed by response at the subse-
quent visit; 13.6%, 14.3% and 16.2%, respectively, of visits 
in which response was the initial state had non-response 
in the subsequent visit, all greater than the corresponding 
percentages for SRI-4.
Using the conventional landmark analytic approach 
with non-responder imputation for missing outcomes, 
the 52-week response rates ranged from 38.0% for BICLA 
(95% CI 33.4% to 42.7%) to 45.9% (95% CI 42.3% to 
49.5%) for SRI-4 (table 3). These estimates are biased 
downwards because all missing outcomes are considered 
non-responses. The corresponding estimates of the prob-
ability of being in response at 52 weeks based on an initial 
two-state MSM model without covariates are higher as 
expected: 50.2% (95% CI 47.1% to 53.5%) for BICLA and 
61% (95% CI 58.3% to 63.5%) for SRI-4. Figure 2 shows 
MSM estimated probabilities of being in the response 
state at all time points during follow-up for the different 
response measures. The trajectories for SRI-5 and SRI-6 
are very similar and both lower than the trends for SRI-4 
and BICLA.
The MSM model can also be used to estimate the 
mean sojourn time for response (the average length of 
time spent in the response state each time response is 
achieved) as well as the mean total time in response over 
52 weeks of follow-up (table 3). The mean sojourn times 
ranged from 20.4 weeks (BICLA) to 31.5 weeks (SRI-4). 
In contrast, the mean total time in the response state 
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Figure 1  Longitudinal patterns of response status: Green=response, Red=no response, Dotted=missing status.
Table 2  Number of transition between response states 
among consecutive visits
Initial state 
Subsequent state, n (row %)
TotalNon-response Response
SRI-4
  Non-response 3735 (82.5) 795 (17.5) 4530
  Response 395 (10.8) 3253 (89.2) 3648
SRI-5
  Non-response 5076 (89.0) 629 (11.0) 5705
  Response 336 (13.6) 2138 (86.4) 2474
SRI-6
  Non-response 5191 (89.3) 621 (10.7) 5812
  Response 339 (14.3) 2028 (85.7) 2367
BICLA*
  Non-response 2392 (83.4) 475 (16.6) 2867
  Response 287 (16.2) 1482 (83.8) 1769
*Among patients with 1A or ≥2B at baseline.
BICLA, BILAG-based Composite Lupus Assessment; SRI, SLE 
Responder Index.
based on all patients including persistent non-responders 
was 16.4–24.8 weeks.
Table 4 shows for different predictor variables the esti-
mated rate ratios for transitioning from non-response 
to response (RR12), and for transitioning from response 
back to non-response (RR21) for SRI-5. RR12 values greater 
than 1 imply higher likelihood of achieving SRI-5 on 
SoC for patients with that characteristic compared with 
the reference group; RR21 values greater than 1 imply 
higher likelihood of leaving the SRI-5 response state 
and shorter response duration. Among all racial groups, 
Asians were the least likely to achieve SRI-5 response on 
SoC at any time (RR12=0.75 compared with Whites; 95% 
CI 0.59 to 0.95). Patients with higher SLEDAI scores were 
more likely to achieve response (RR12=1.09 per 1 point 
increase in score; 95% CI 1.06 to 1.11) as well as remain 
in the response state (RR21=0.88; 95% CI 0.84 to 0.92), 
consistent with prior findings of increased response 
rates in those with higher disease activity at entry.10 In 
contrast, patients who were of African descent (RR21=1.76 
compared with Whites; 95% CI 1.23 to 2.52), had a longer 
history of disease (RR21=1.27 per 10 years increase; 95% CI 
1.07 to 1.51) and had anti-dsDNA titres of at least 30 IU/
mL (RR21=1.40; 95% CI 1.07 to 1.81) were more likely to 
revert back to non-response after response was achieved.
Patients with higher lymphocyte counts (RR21=0.72 per 
unit increase; 95% CI 0.60 to 0.86) and higher haemo-
globin (RR21=0.90 per unit increase; 95% CI 0.83 to 0.98) 
were more likely to remain in response, that is, have 
longer response durations. Higher anti-SSARo antibody 
titres were weakly associated with higher probability of 
response (RR12=1.02 per 10 units increase; 95% CI 1.00 to 
1.03). Younger age and higher protein/creatinine ratio 
(PCr) were associated with higher likelihood of achieving 
SRI-5 response (RR12=0.85 for age per 10 years increase; 
95% CI 0.78 to 0.92; RR12=2.20 for PCr>500 mg/g; 95% 
CI 1.66 to 2.92), and of transitioning back to non-re-
sponse (RR21=0.88 for age per 10 years increase; 95% CI 
0.79 to 0.98; RR21=2.16 for PCr>500 mg/g; 95% CI 1.51 
to 3.10). The association with age could reflect more 
aggressive treatment of younger patients, and only tran-
sient amelioration by steroids as they were withdrawn. Of 
note, patients who received mycophenolate mofetil were 
younger than those who did not (mean age: 36.5 vs 40.1 
years, respectively; p=0.01).
To examine differences in findings between the MSM 
and the usual cross-sectional analysis of data from a single 
visit with missing outcomes analysed as non-responses, 
we also fit a logistic regression model that included the 
same predictor variables as before, but with 52-week 
response status as the outcome. Baseline characteristics 
associated with significantly increased likelihood of being 
a responder at 52 weeks (table 4) include higher SLEDAI 
(OR=1.11 per 1 point increase; 95% CI 1.06 to 1.17), 
higher lymphocyte count (OR=1.28; 95% CI 1.01 to 1.62) 
and higher haemoglobin (OR=1.14; 95% CI 1.01 to 1.28). 
None of the other laboratory measures (anti-dsDNA, PCr, 
anti-SSARo) that were significant in the MSM analysis 
were found to be predictive of 52-week response status in 
the logistic regression analysis.
We had assumed that the baseline transition inten-
sities are constant over time by fitting a time-homoge-
neous Markov model. Since adjustments to steroid doses 
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Table 3  Estimated response rates and duration of response for different responder indices
Responder
index
Landmark response rate 
at 52 weeks*
Probability in response 
at 52 weeks from MSM
(95% CI)
Mean sojourn time in 
response
(95% CI)
Mean total time in 
response
(95% CI)
SRI-4
45.9% 
(95% CI 42.3% to 49.5%)
61.0% 
(95% CI 58.3% to 63.5%)
31.5 weeks 
(95% CI 28.5 to 34.8)
24.8 weeks 
(95% CI 23.7 to 25.9)
SRI-5
33.6% 
(95% CI 30.2% to 37.1%)
43.6% 
(95% CI 40.8% to 46.3%)
25.7 weeks 
(95% CI 23.1 to 28.7)
17.1 weeks 
(95% CI 16.0 to 18.1)
SRI-6
32.5% 
(95% CI 29.2% to 36.0%)
41.7% 
(95% CI 38.8% to 44.7%)
24.3 weeks 
(95% CI 21.9 to 27.1)
16.4 weeks 
(95% CI 15.3 to 17.5)
BICLA†
38.0% 
(95% CI 33.4% to 42.7%)
50.2% 
(95% CI 47.1% to 53.5%)
20.4 weeks
(95% CI 18.1 to 23.0)
21.2 weeks
(95% CI 19.7 to 22.5)
*Dropouts and missing data imputed as non-response.
†Among patients with 1A or ≥2B at baseline.
BICLA, BILAG-based Composite Lupus Assessment; MSM, multistate model; SRI, SLE Responder Index.
Figure 2 Prevalence of responders by week. BICLA, BILAG-
based Composite Lupus Assessment; SRI, SLE Responder 
Index.
were allowed during the first 24 weeks, we relaxed the 
time-homogeneous assumption in sensitivity analyses and 
fit a two-state Markov model which allowed the transition 
intensities to be piecewise constant between 0–12 weeks, 
12–24 weeks and >24 weeks. The results were nearly iden-
tical to those of the time homogeneous two-state model 
(online supplementary table 1).
dIsCussIOn
The within-subject variability in response to therapy 
over time has not been adequately explored in prior 
SLE trials, which have tended to focus primarily on 
cross-sectional response status at specific visits. We 
recently evaluated longitudinal patterns of the response 
to SoC in a smaller group of subjects and demonstrated 
the lack of stability in response status over time and 
the weak correlation between outcomes measured at 
earlier and later visits.5 In this paper, we used an MSM 
approach to make better use of complex longitudinal 
clinical trial data and obtain a more comprehensive view 
of the response profile. The MSM method yielded for 
different response measures estimates of both average 
duration of response in SoC and total time in response 
over 52 weeks, which have not been assessed in prior 
trials. We also showed that characteristics associated 
with greater disease severity were consistently predictive 
of shorter response duration on SoC despite exhibiting 
variable effects on the probability of achieving response 
at a given time, underscoring that a simple cross-sec-
tional analysis may provide an incomplete and poten-
tially misleading picture of the influence of different 
factors on disease outcomes.
Some of the significant predictors of achieving and 
losing response that were identified in our MSM analysis 
are consistent with well-established prognostic factors for 
SLE. But knowing the features that permit or prolong 
response to SoC in the clinical trial setting is helpful 
for the design of future trials that aim to enrich popu-
lations for those less likely to respond to SoC and who 
would benefit most from experimental therapies. Our 
results indicate that patients from minority groups and 
those with higher anti-dsDNA antibody titres are less 
likely to achieve and maintain response on SoC. In addi-
tion, the association of higher SLEDAI scores with higher 
likelihood of responding and staying in response seems 
clinically counterintuitive, but the patients with higher 
scores may be receiving more aggressive SoC, and they 
can meet the thresholds required for achieving response 
(eg, reduction in SLEDAI by at least 4 points for SRI-4) in 
more ways given the way SLEDAI is scored.
We also found that older patients were less likely to 
respond but were more likely to maintain response once 
it is achieved. A possible explanation is that a subset of 
older patients who were enrolled in the trial were misclas-
sified as having SLE and therefore would not respond 
to SoC, but the ones who did respond have more stable 
disease and more durable responses than younger 
patients. Patients with higher lymphocytes and higher 
haemoglobin tend to be healthier and were observed in 
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Table 4  Predictors of transitions between SRI-5 response states
Predictor
Non-response to
response
Response to
non-response
P values†
Logistic regression
SRI-5 at 52 weeks (n=746)
RR12 (95% CI)* RR21 (95% CI)* OR (95% CI) P values‡
Race
  White 1 1 0.005 1 0.03
  Black 0.83 (0.62 to 1.10) 1.76 (1.23 to 2.52) 0.61 (0.36 to 1.06)
  Asian 0.75 (0.59 to 0.95) 1.29 (0.95 to 1.74) 0.62 (0.38 to 1.02)
  Native American 0.96 (0.76 to 1.23) 0.83 (0.58 to 1.18) 1.31 (0.82 to 2.10)
Age (per 10 years increase) 0.85 (0.78 to 0.92) 0.88 (0.79 to 0.98) <0.0001 0.93 (0.80 to 1.08) 0.33
Disease duration (per 10 years 
increase)
1.00 (0.87 to 1.14) 1.27 (1.07 to 1.51) 0.025 0.80 (0.62 to 1.03) 0.09
SLEDAI (per 1 point increase) 1.09 (1.06 to 1.11) 0.88 (0.84 to 0.92) <0.0001 1.11 (1.06 to 1.17) <0.0001
Anti-ds DNA (≥30 vs <30 IU/mL) 1.09 (0.90 to 1.31) 1.40 (1.07 to 1.81) 0.039 1.20 (0.84 to 1.72) 0.32
Protein/creatinine ratio (>500 
mg/g)
2.20 (1.66 to 2.92) 2.16 (1.51 to 3.10) <0.0001 1.11 (0.60 to 2.05) 0.74
Lymphocyte count (per 1 unit 
increase)
0.98 (0.86 to 1.11) 0.72 (0.60 to 0.86) 0.0008 1.28 (1.01 to 1.62) 0.043
Haemoglobin (per 1 unit 
increase)
1.05 (0.99 to 1.11) 0.90 (0.83 to 0.98) 0.006 1.14 (1.01 to 1.28) 0.032
Anti-SSARo (per 10 units 
increase)
1.02 (1.00 to 1.03) 1.00 (0.98 to 1.02) 0.044 1.01 (0.98 to 1.03) 0.70
*RR
ij
=Rate ratio of transitioning from state i to j.
†Likelihood ratio test.
‡Wald test.
SLEDAI, SLE Disease Activity Index; SRI, SLE Responder Index.
our analyses to more likely maintain response. Many of 
these associations revealed in the MSM analysis were not 
detected by the logistic regression analysis of the 52-week 
response status.
A major challenge in the identification of effective 
new therapies for SLE is the inherent heterogeneity and 
fluctuation in symptoms that lupus patients can experi-
ence over time. Standard cross-sectional approaches for 
analysing SLE trials can estimate only the proportion 
of individuals in response at a given visit, whereas the 
MSM model provides additional clinically important 
information about the average duration of response 
and the total time that patients spend in response over 
a given period. By maximising the use of all the longi-
tudinal disease activity data obtained during follow-up, 
the MSM method may also be a more powerful way to 
distinguish effective investigational treatments from 
background SoC. This will be confirmed in future 
research with data from both the experimental and 
control arms of SLE trials.
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